Anti-Mouse LPAM-1- Purified In vivo PLATINUM Functional Grade

Antibody Details

Product Details

Reactivity Species

Mouse

Host Species

Rat

Immunogen

TK1 cells

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

< 0.5 EU/mg as determined by the LAL method

Purity

≥98% monomer by analytical SEC

⋅

> 95% by SDS Page

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

2-8°C

RRID

AB_2893872

Applications and Recommended Usage?
Quality Tested by Leinco

FC The suggested concentration for this DATK32 antibody for staining cells in flow cytometry is ≤1.0 µg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.

Other Applications Reported In Literature ?

B This antibody has been reported to block α4β7 mediated lymphocyte adhesion to VCAM-1, MAdCAM-1, and fibronectin for In vitro and In vivo studies.
IHC FF
IP

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Clone DATK32 recognizes an epitope specific to the mouse LPAM-1 heterodimer.

Antigen Distribution

LPAM-1 is expressed on most peripheral lymphocytes, subsets of thymocytes, and bone marrow progenitor cells.

Background

LPAM-1 antibody, clone DATK32, recognizes mouse lymphocyte Peyer’s patch adhesion molecule (LPAM-1), also known as integrin alpha 4 beta 7 (α4β7). LPAM-1 is a heterodimer of the 154 kDa integrin α4 (CD49d) and 130 kDa integrin β7 chains and is a member of the Ig superfamily. LPAM-1 is expressed on most peripheral lymphocytes, subsets of thymocytes, and bone marrow hematopoietic stem cells^{1, 2}. LPAM-1 mediates adhesion to endothelial cells, promoting leukocyte transmigration across high endothelial venules (HEVs) during the inflammatory response. LPAM-1 binds to several ligands, including vascular adhesion molecule-1 (VCAM-1/CD106), mucosal addressin cell adhesion molecule-1 (MAdCAM-1), and fibronectin. MAdCAM-1 is expressed exclusively on endothelial cells of the gut and gut-associated lymphoid tissues, such as Peyer’s patches (PPs), and binding of LPAM-1 to MAdCAM-1 contributes to lymphocyte homing to mucosal tissues^{3, 4}. Vedolizumab, an anti-LPAM-1 monoclonal antibody, is approved to treat inflammatory bowel disease and effectively induces and maintains remission in Crohn's disease and ulcerative colitis^5-8.

Antigen Details

Protein

LPAM-1

Ligand/Receptor

VCAM-1 (CD106), MAdCAM-1, fibronectin

Function

Lymphocyte adhesion

PubMed

LPAM-1

NCBI Gene Bank ID

311144

UniProt.org

Information on Uniprot.org

Research Area

Cell Biology

.

Immunology

.

Neuroscience

References & Citations

1. Andrew DP, et al. (1996) Eur J Immunol. 26(4):897-905
2. Murakami JL, et al. (2016) Stem Cells Dev. 25(1):18-26
3. Hu MC, et al. (1992) Proc Natl Acad Sci USA. 89(17):8254-8
4. Hamann A, et al. (1994) J Immunol. 152(7):3282-93
5. Sandborn WJ, et al. (2013) N Engl J Med. 369:711–721
6. Feagan BG, et al. (2013) N Engl J Med. 369:699–710
7. Kopylov U, et al. (2019) Dig Liver Dis. 51:68–74
8. Danese S, et al. (2019) Gastroenterology.157:1007–1018 e1007

Technical Protocols